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Summary When cyclophosphamide (CY) (100-120 mg kg-') was administered intravenously (i.v.) to normal F-344 rats, oliguria occurred over
the 5-day observation period. Conversely, in rats bearing matrix metalloproteinase-9 (MMP-9) producing 13762NF mammary adenocarcinoma
(MTLn3 clone), polyuria occurred chiefly during the first 24 h after CY treatment. In parallel with urine volume, a decrease in the urinary
excretion of Nacetyl-beta-D-glucosaminidase (NAG) was observed during the first 5 days after CY treatment in normal rats, but it increased in
MTLn3-bearing rats. No elevation in blood urea nitrogen (BUN) or serum creatinine (Cr) values was observed for either group. Both urine
volume and urinary excretion of NAG after CY treatment were lower in rats bearing the MTC clone (lower production of MMP-9) than for those
bearing the MTLn3 clone. In the case of treatment with cisplatin (CDDP, 4-6 mg kg-'), urine volume, urinary NAG excretion and BUN and
serum Cr values all increased in normal rats and were all found to be higher in MTLn3-bearing rats than in normal rats. The diuretic response
to these drugs in tumour-bearing (TB) rats may be associated with MMP-9 produced by the tumour cells. This report suggests that the
nephrotoxicity due to anti-cancer drugs may change when the drugs are used forthe treatment of patients bearing a MMP-9-producing tumour.
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The destruction of extracellular matrix components is the primary
process in tumour invasion and metastasis. The close association
between the metastatic potential of tumour cells and activities of
extracellular matrix degradative enzymes has been reported in a
varietx of malignant tumours (Liotta et al. 1980. 1990: Levy et al.
1991: Yamagata et al. 1991: Stetler-Stesenson et al. 1993: Zucker
et al. 1993: Gohji et al. 1994-. Among several matrix metallopro-
teinases (MMPs). MMP-7. MMP-9 and MT-MMP are reported to
be representative of the ones which the tumour itself produces.
While carrying out experimental chemotherapy using an MMP-9-
producing tumour (13762NF. MTLn3 clone) in rats. ve came up
with the simple question of how the toxic side-effects of anti-
cancer drugs would be modified in hosts bearing MMPs-
producing tumours. As no studx could be found to answer our
question. vie initiated our own experiments on rats. At first. we
planned to define the influence of MMP-9 on cyclophosphamide
(CY -induced haemorrhagic cystitis (Philips et al. 1961:
Meisenberg et al. 1994) and started to measure the haemoglobin
le,vel in urine. In the course of the experiments. we found a large
discrepancy in urine volume between normal and MTLn3-bearing
rats after CY treatment. In this report. wve demonstrate that nephro-
toxicity. as a result of treatment by cvclophosphamide (CY) or
cisplatin (CDDP). may be radically modified in hosts bearing
MMPs-producing tumours.
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MATERIALS AND METHODS
Animals
Male F-344 rats wvere obtained from the SCL. Shizuoka. Japan.
Experimental rats were 12-14 vieeks old. weighed '30-2'0 and
were kept in a clean animal room.
Anti-cancer drugs
C clophosphamide (CY) w as administered intravenouslv (i.v.) in
a volume of 1 ml per 200 ofbodx weight for each rat through the
tail vein. and cisplatin (CDDP) in a volume of 5 ml per rat
intrapenitoneally- (i.n. ).
Tumours
The 13762NF tumour is a mammar- adenocarcinoma derixved from a
F-344 rat. The MTC clone was established from a local mammar- fat
pad site and MTLn3 from a spontaneous lung metastasis site. both of
wvhich were kindlv donated bv Dr GL Nicolson (USA). The MTLn3
clone produces a larger amount of MMP-9 and is more metastatic
than the MTC clone (Nakajima et al. 1987. 1993). The expression of
the MMP-9 gene measured by the reverse transcriptase poly-merase
chain reaction (RT-PCR) method (RNA-PCR kit Takara. Japan) in
our laboratory. vas found to be around tu-ice as hirh for the MTLn3
clone compared with the MTC clone. The mRNA for MMP-2 was
not detected bv the RT-PCR method in both clones. Tumour cells
vere inoculated subcutaneouslv (s.c.) in the right flank ofthe rat and
tumour size (mm) was expressed as (short diameter + long diam-
eterV/2. When 2 x I0 of MTLn3 or MTC cells were inoculated s.c..
the mean survival time was around 45 and 60 da s respectively.
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Collection of urine and blood
Each rat was kept in a metabolic cage and urine was collected at
24-h intervals for 5 days. Blood was collected from the tail vein
and the sera were analvsed.
Measurement of N-acetyl-beta-o-glucosaminidase
(NAG) activity
NAG activitv in urine was measured by the colorimetric assax using
NAG Rate Test Shionogi (Shionogi. Japan) (Noto et al. 1983).
A
50 -
-3 40-
0 a.
a
CD 30-
E
3
0
-= 20-
Statistical analysis
Data are shown as means ± s.e. Results were statisticallx evaluated
bv the Student's t-test. and a P < 0.05 level of significance was
adopted throughout the study.
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RESULTS
Antidiuretic response to CY in normal rats and diuretic
response to CY in MTLn3-bearing rats
When CY (100 mg kg-') was administered i.x. to normal rats. their
unne volume during the first 24 h decreased from 6.9 ml to 3.7 ml.
Converselv. in MTLn3-bearing rats. polyuria occurred dungn the
first 24 h after CY treatment: unrne volume was 34.7 ± 8.4 ml for
tumour-bearing rats on dav 14 (TB-14 rats) and 19.6 ±2.0 ml
for TB-21 rats (Figure IA). Specific gravity of the unrne was
1.038 ± 0.004. 1.063 ± 0.003 and 1.014 ± 0.002 for the normal
control rats. CY-treated non-TB rats and CY-treated TB-14 rats
respectively. There was no significant diference in urine volume
between normal and TB rats up to 21 days aftertumour inoculation.
Following CY treatment. oliguria in normal rats and polyuria
in TB rats became apparent when their 5-d urine volumes
were compared (Figure 1B). Five-day urine volume taken after
CY (100 mg kg-1) treatment decreased from 22.1 ± 1.6 ml to
7.6 ± 1.1 ml (P < 0.001) for normal rats. but it showed an increase
to 58.5 ± 9.5 ml (P < 0.01 ) for TB-14 rats. Similar findings were
also observed in the unrne volumes with the administration of
120 mg kg-' ofCY. but not for 80 mg kg-I CY.
Urinarv NAG excretion was measured to assess the renal tubular
damage (Figure 2) (Naruse et al. 1981: Valentovic et al. 1994).
NAG excretion (5 davs) afterCY (100-120 mg kg-') treatment was
significantly lower in non-TB rats than in normal control rats. and
was significantly higher in TB rats than in normal control and non-
TB rats. CY. at a dose of 80 mg kg-'. did not cause any significant
changes in urinarv NAG excretion in normal and TB rats.
Changes in biochemical substances in sera after tumour inocula-
tion are shown in Table 1. As the tumour grew larger. total protein
values decreased. but BUN and Cr values were relatively stable.
When CY (80-120mg kg,-') was administered i.-. to normal or
TB-14 rats. no significant changes in the serum values ofBUN. Cr
or other substances were obser ed in either group.
Diuretic response to CY in rats bearing the MTC clone
The effects of CY on urine volume and urinary NAG excretion
were examined im F-344 rats beanrng the MTC clone. which has a
capacity to produce a lesser amount of MMP-9 than the MTLn3
clone. The MTC tumour grew much more slowly than the MTLn3
tumour. therefore CY (100 mg kg-') was administered on day 25 or
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Figure 1 (A) Changes in urine volume during 5 days after administration of
100 mg kg-, of CY in normal and MTLn3 tumour-bearing F-344 rats. Each
group consisted of 5-7 animals. N = non-TB rats, TB-14 (21) = CY was
administered on day 14 (21) after inoculation of tumour cells. The number on
the abscissa means the day after CY administration. (B) Effects of different
doses of CY (80-120 mg kg-') on unne volume (5 days) in normal and
MTLn3 tumour-bearing F-344 rats. Each group consisted of 5-7 animals.
*Statistically significant vs the CY-treated N rats. "Statistcalty significant vs
the CY-untreated N rats (normal control)
on day 42 after tumour inoculation (Table 2). In MTC-bearing rats.
unne volume and urinarv NAG excretion after CY treatment were
higher than in normal rats. but lower than in MT1-n3-bearing rats.
Nephrotoxic effect of CDDP
Nephrotoxicity from CDDP is well known (Mizushima et al. 1987:
Meyer and Madias. 1994: Leibbrandt et al. 1995). Thus. we
compared the nephrotoxic effect of CY with that of CDDP (at
levels of 4 and 6 mg kg-') in F-344 rats. In contrast to CY. a
diuretic response occurred in normal rats after CDDP treatment:
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Figure 2 Urinary NAG excretion (5 days) after CY (80-120 mg kg-')
administration in nomial and MTLn3 tumour-bearng F-344 rats. Each group
consisted of 5-7 animals. 'Statistically signficant vs the CY-treated N rats.
**Statistically significant vs the CY-untreated N rats
urine Xolume (nml per 5 days) increased from 22.1 ml to 30.8 ml for
4 mg kg-I CDDP and to 33.5 ml (P < 0.05) for 6 mg kga-' ofCDDP
(Figure 3). Urinary NAG excretion (x I0- U per 5 days) also
increased from 391 to 653 (P < 0.05) for 4 mg kg-' CDDP and to
670 (P < 0.05) for 6 mg kg-' (Table 3). These increases w-ere all
larger in the TB (MTLn3)-14 rats than in non-TB rats. BUN and
Cr values also tended to be higher in the TB (NMTLn3 -l4 rats than
in non-TB rats.
DISCUSSION
We have shown in this study that there wVas a large discrepancy in
urine Xolume between normal rats and rats bearing MMP-9-
producina tumour after CY treatment. Nephrotoxicity due to CY
and its analoaue of ifosfamide has been well documented in both
man and animals (Lopes. 1967: Lavin and Koss. 1970: Goren et al.
1987: Henev et al. 1989: Patterson and Khojasteh. 1989). After
Table 2 Effects of CY on urine volume and urinary NAG excretion in F-344
rats bearing the MTC clone (lower MMP-9 production)
Treatment Tumours size Unne volume NAG (x 10 3 U
(mm) (ml per 5 days) per 5 days)
N: None 22.1 ± 1.6 391 -31
N: CY 100mg kg-' 7.6+1.1 152z22
TB (MTC)-25: CY 100a 20.5 0.3 22.1 ± 2.8t 370 + 606
TB(MTC)-42:CY 100 32.8 1.9 32.9 7.6 - 582 133c
TB (MTLn3)-14: CT 100 24.3 + 1.1 58.5 9.5 703 t68
TB (MTLn3)-21: CY 100 30.0 - 1.5 45.9 9.8 662 137
aMTC tumour cells 2 x 10o s.c. on day 0. CY was administered i.v. on day 25
(TB-25) or on day 42 (TB-42). Each group consisted of five rats. tp< 0.01.
;P< 0.05 vs the CY-treated N group.
CY treatment. oliouria occurred in nonnal rats. and this findin2
was in aareement with the report by Steele et al (1973).
Conversely. poly-una occurred in rats bearingc MMP-9-producina
tumour. It is generally accepted that oliguria is caused by acute
tubulardamage. Lavin and Koss ( 1970) reported. based on an elec-
tron microscopic study in rats. that the most striking changes in
cell necrosis and desquamation caused by CY (200 mg kg-1) treat-
ment were found in the proximal tubules: changes in the distal
tubules were not as prominent as those in the proximal tubules and
no significant evidence ofdamaae was found in the alomeruli. The
fact that oliguria or polyuria after CY treatment was not associated
with an elevation of BUN or Cr in our study also supports a renal
tubular defect. We are now- inM estigating the histopathology of the
affected kidney.
What are the mechanisms for diuresis after CY treatment in rats
bearing MMP-9-producing tumour? The tumour-bearing state itself
does not seem to be responsible for polyuria. because polyuria
occurred only when the pertinent drug was administered to TB rats.
Serum levels ofpotassium and calcium were within normal range in
TB-14 rats: sodium = 146 mequiv. 1-1 (normal rats = 141). potassium
= 5.2 (5.6) mequiv. 1-'. calcium = 4.5 (5.2) mequiv. 1-'. bloodglucose
= 85 (150) mg dl'. Therefore. neither hypokalaemic nephropathy
norhypercalcaemic nephropathy seems alikely cause ofpolyuria and
nor does hyperglycaemia. At the present time. we have no clear
explanation for the nephrogenic diabetes inspidus-like phenomenon
Table 1 Biochemical data in F-344 rats treated with CY
Tumour size (mm) T-P (mgdl-1) GOT (IU) GPT (IU) ALP (IU) BUN (mgd[1) Cr (mg dl-')
Normal (N) 7.0±0.2 158+24 49+3 582+93 20+1 0.5+0.0
TB-7 10.0 0.4 7.0t0.1 139+10 47_2 568+8 20+0 0.5+0.0
TB-14 22.7+1.3 7.1 ± 0.4 235+36 68±20 327+42 20+2 0.6+0.1
TB-21 29.0 2.0 6.1 -0.2t 206+26 43+6 545+90 20 1 0.5+0.0
TB-28 34.7 2.0 5.8 0.2c 318 ± 31: 46 _3 904 ± 137 16±1: 0.5 0.0
CY 80 mg kg-: N-5a 6.5 0.3 124 ± 21 85 + 36 522 20 22 2 0.65 0.08
CY80mg kg-:TB-19 6.4+0.3 134_±27 54_12 266±60 19+1 0.50+0.05
CY100:N-5 6.4+0.3 110-15 51_3 401-25 24-6 0.70
- 0.16
CY100:TB-19 6.7_0.3 127+16 47_4 229 28 15+2 0.50-0.0
CY 120: N-5 6.7 0.2 108 -12 50 ± 3 356 21 20 ± 2 0.58 + 0.05
CY 120: TB-19 6.6±0.2 144-9 47_4 211 25 17_1 0.48±0.02
-TB. tumnour-bearing rats: N, non-TB rats. MLTn3 tumour cells 2 x 106 s.c. on day 0. and CY i.v. on day 14. Blood was collected 5 days after CY administration
(TB-19). As a control, non-TB rats were used (N-5). Each group consisted of 5-7 rats. bp < 0.01, cP< 0.001 vs the normal group. T-P. total protein; GOT.
glutamic oxaloacetic transaminase; GPT, glutamic pyruvic transaminase: ALP. alkaline phosphatase; BUN, bk)od urea nitrogen; Cr, creatinine
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Figure 3 Changes in urine volume during 5 days after administration of
CDDP (4 or 6 mg kg-') in normal and MTLn3 tumour-bearing rats. Each
group consisted of 5-7 animals. The number on the abscissa means the day
after CDDP administration and 1-5 means the total volume of urine after
5 days. *StatisticalJy significant vs the CDDP-treated N rats. -Stabstically
significant vs the CDDP-untreated N rats
resulting from CY treatment. We speculate that MMP-9 may be
responsible for the diuretic response to CY. MMP-9 has type IV
collagenolytic enzyme activities, which are capable of degradin,
basement membrane components. If the nephrotoxic effect of CY
reached the distal tubules or collecting tubules whose basement
membrane components had been damaged by MMP-9. polyuia
instead of oliguria may have resulted because of the impairment of
reabsorptive functions in TB rats. The fact that the urine volume was
much larger in rats bearing the MTLn3 clone (high production of
MMP-9) than in rats bearing the MTC clone (low production of
MMP-9) also seems to support this speculation. Clinically. nephro-
toxicity from CDDP is more common than that from CY. and the
occurrence of proximal tubular necrosis in CDDP-treated rats has
been well documented (Safirsten et al. 1986: Wolfgang et al. 1994:
al-Harbi et al. 1995). Therefore. we also examined the nephrotoxic
effect of CDDP in TB rats. There were some differences in nephro-
toxicitybetween CY andCDDP In normal rats. poly-uria andmarked
elevations of BLJN and Cr occurred after CDDP. which were not
observed with CY. These indices were further enhanced in MTLn3-
bearing rats than for non-TB rats. which also sugrgests that MMP-9
might enhance the renal toxicity due to CDDP. Early polyuria
following CDDP administration is well documented. Clifton et al
(1982) reported that the CDDP-induced polyuria was caused by the
inhibition ofantidiuretic hormone (ADH) release. but Daugaard et al
(1986) stated that this possibility seemed unlikely. Ohta et al (1991)
reported that production ofendothelin. a mediator ofrenal v-asocon-
striction. could be associated with the CDDP nephrotoxicity. More
detailed studies will be required to define the mechanism.
Type IV collagenolytic activity was detected in plasma from
MTLn3-bearing, rats by means ofzymography in ourlaboratory. as
already shown by Nakajima et al (1993). MMPs activities are
regulated by the tissue inhibitors of metalloproteinases (TIMP-1.
TIMP-2) (Kodama et al. 1989: Boone et al. 1990). We speculate
that MMP-9 is responsible for some reactions taking place in viVo
in TB hosts. However. the augmentation of side-effects by anti-
cancer drugs in MMP-9-bearinr hosts seems to relate to organs.
In preliminary experiments. we examined the hepatotoxicitv of
v-indesine sulphate (VDS) in normal and TB rats. VDS has
been proved to cause hepatotoxicitv in this strain of rat in our
laboratory. No evident difference in hepatotoxicitv was observed
between the two groups. In other words. the type IV collagenolytic
activity did not seem to relate to the hepatotoxicity. We speculate
that this was because liver and kidney are histologrically different:
liv-er will be less affected by MMP-9 than kidney.
This report proposes the possibility that the effects of anti-
cancerdrugs on some normal tissues may be augmented by MMPs
originated from tumour cells. Zucker et al (1993) reported that
overproduction of MMP-9 occurred in colon cancer and breast
cancer in humans. However. this possibility has not been noticed
clinically so far. It is certainly feasible. we think. that some of the
variability in the nephrotoxicitv of anti-cancer drurs could be due
to tumour factors. We should be aware of the side-effects of anti-
cancer drugs when we treat a patient with an MMPs-producing
tumour with anti-cancer drugs.
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